Transfer of FTSE classification to Healthcare

24 September 2018

Cello Health plc

("Cello" or the "Group")

Transfer of FTSE sector classification to Healthcare

Cello Health plc (AIM: CLL), the healthcare-focused advisory group, is pleased to announce that its FTSE sector re-classification from the Media sector (5550) to the Healthcare Equipment and Services sector (4530) became effective today, Monday 24 September 2018.

Mark Scott, Cello's Chief Executive, commented: "I welcome the re-classification of Cello's sector on the London Stock Exchange to Healthcare as it more accurately reflects the Group's business model, with the majority of the Group's revenues and profits being derived from clients in the Healthcare sector through our Cello Health brand, supported by a growing health capability delivered through our Signal brand."

Enquiries:

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com